Yunki Y Yau

List of Publications by Year
in descending order

16 papers	296 citations	1163117 8 h-index	996975 15 g-index
16 all docs	16 docs citations	16 times ranked	560 citing authors

#	Article	IF	Citations
1	Molecular Pathophysiology of Epithelial Barrier Dysfunction in Inflammatory Bowel Diseases. Proteomes, 2018, 6, 17.	3.5	77
2	Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Alimentary Pharmacology and Therapeutics, 2021, 54, 292-301.	3.7	39
3	Proteomics and metabolomics in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1076-1086.	2.8	32
4	Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective. Molecular and Cellular Proteomics, 2016, 15, 256-265.	3.8	30
5	Full-Spectrum Endoscopy Improves Surveillance for Dysplasia in Patients With Inflammatory Bowel Diseases. Gastroenterology, 2017, 152, 1337-1344.e3.	1.3	30
6	Knowledge and Attitudes Towards Pregnancy in Females with Inflammatory Bowel Disease: An International, Multi-centre Study. Journal of Crohn's and Colitis, 2020, 14, 1248-1255.	1.3	27
7	Serological Epithelial Component Proteins Identify Intestinal Complications in Crohn's Disease. Molecular and Cellular Proteomics, 2017, 16, 1244-1257.	3.8	13
8	Spp24 is associated with endocytic signalling, lipid metabolism, and discrimination of tissue integrity for 'leaky-gut' in inflammatory bowel disease. Scientific Reports, 2020, 10, 12932.	3.3	13
9	Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2018, 30, 735-740.	1.6	10
10	Bimodal plasma metabolomics strategy identifies novel inflammatory metabolites in inflammatory bowel diseases. Discovery Medicine, 2014, 18, 113-24.	0.5	7
11	Proteomics in Inflammatory Bowel Disease: Approach Using Animal Models. Digestive Diseases and Sciences, 2017, 62, 2266-2276.	2.3	6
12	Current Trends in IBD—Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System. Inflammatory Bowel Diseases, 2021, 27, S17-S24.	1.9	6
13	Reverse-Polynomial Dilution Calibration Methodology Extends Lower Limit of Quantification and Reduces Relative Residual Error in Targeted Peptide Measurements in Blood Plasma. Molecular and Cellular Proteomics, 2015, 14, 441-454.	3.8	3
14	Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission—confounded by the gut microbiome?. Alimentary Pharmacology and Therapeutics, 2019, 49, 1086-1087.	3.7	2
15	Reflux scintigraphy in gastro-esophageal reflux disease: a comparison study with 24‰hour pH-impedance monitoring. Scandinavian Journal of Gastroenterology, 2022, , 1-5.	1.5	1
16	IDDF2019-ABS-0042…Prospective study of risk score strategies in the prediction of advanced colorectal neoplasia at colonoscopy. , 2019, , .		0